Paper Details 
Original Abstract of the Article :
This case report evaluates the potential benefit of pitolisant in a 15-year-old female with Prader-Willi syndrome, obsessive-compulsive disorder, autism spectrum disorder, and mild intellectual disability. Due to its action on the H3 receptor, it enhances central activity of histaminergic neurons re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139568/

データ提供:米国国立医学図書館(NLM)

Pitolisant for Prader-Willi Syndrome: A Promising Treatment

Prader-Willi syndrome is a rare genetic disorder that can lead to a range of challenges, including excessive hunger, obesity, and developmental delays. This study examines the potential benefits of a medication called pitolisant for treating symptoms in a 15-year-old girl with Prader-Willi syndrome, obsessive-compulsive disorder, autism spectrum disorder, and mild intellectual disability.

Pitolisant's Mechanism of Action

Pitolisant works by activating histaminergic neurons, which are involved in alertness and other brain functions. It is thought to improve symptoms of Prader-Willi syndrome by modulating various neurotransmitter systems, including acetylcholine, norepinephrine, and dopamine.

Potential Benefits and Tolerability

The results of this case report suggest that pitolisant may be a promising treatment option for patients with Prader-Willi syndrome. The patient in this study tolerated pitolisant well, with minimal side effects.

Dr.Camel's Conclusion

This research, like a single oasis in the vast desert of Prader-Willi syndrome, offers a glimmer of hope for patients struggling with the challenges of this disorder. While more research is needed to confirm its efficacy and safety, pitolisant may provide a new avenue for addressing the multifaceted symptoms of Prader-Willi syndrome.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-05-28
Further Info :

Pubmed ID

34035686

DOI: Digital Object Identifier

PMC8139568

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.